Retinal implant for individuals with late-stage retinitis pigmentosa
If you have late-stage retinitis pigmentosa (RP), you may be a candidate for the Argus® II Retinal Prosthesis System (Argus II), a retinal implant that could provide partial sight for individuals with the disease.
Sometimes referred to as an artificial retina or “bionic eye,” the Argus II was approved by the Food and Drug Administration in February 2013. It was developed by Second Sight Medical Products, Inc. and is now offered at the University of Michigan Kellogg Eye Center, one of 13 major centers across the country to offer the implant.
What to Expect
The retinal implant should allow you to perceive light and objects, and achieve greater independence in your daily activities. In a clinical study, most participants were able to perform basic activities better with the retina prosthesis than without it. Many were able to locate lights and windows, follow lines in a crosswalk, or avoid running into things as they walked. Some could sort laundry or determine where other people were located in a room, and about half of the subjects were able to read very large letters (about 9 inches high).
Are you a candidate for the retinal implant?
The implant is currently approved and intended for use in patients with severe to profound retinitis pigmentosa who meet the following criteria:
- Age 25 years or older.
- Have RP that has progressed to the point of having “bare light” or no light perception in both eyes.
- A previous history of useful form vision.
- Aphakic or pseudophakic, meaning the patient does not have a natural lens, often because it’s been replaced with an IOL after cataract surgery. (If the patient is phakic prior to implant, the natural lens will be removed during the implant procedure.)
- Be willing and able to receive the recommended post-implant clinical follow-up, device fitting, and visual rehabilitation.
If you would like more information, please contact:
Kellogg Eye Center Retinal Dystrophy Clinic